1. Maintenance of Investigator’s Static Global Assessment Response with Once-Daily Crisaborole in Participants with Mild to Moderate Atopic Dermatitis
- Author
-
Lawrence F. Eichenfield, Linda F. Stein Gold, Charles Lynde, Lyn Guenther, Shoshana Greenberger, Chia-Yu Chu, Zara Ghodsi, Bonnie Vlahos, Paul Sanders, Amy Cha, and Juliana M. Canosa
- Subjects
Anti-inflammatory agents ,Atopic dermatitis ,Crisaborole ,Disease control ,Flare ,Investigator’s Static Global Assessment ,Dermatology ,RL1-803 - Abstract
Abstract Introduction Treatments for atopic dermatitis (AD) often fail to achieve lasting disease control. In the CrisADe CONTROL phase III study (ClinicalTrials.gov: NCT04040192), participants aged ≥ 3 months with mild to moderate AD treated with once-daily (QD) crisaborole, following initial treatment success with crisaborole twice daily (BID), had longer periods of flare-free maintenance, a higher number of flare-free days, and a lower number of flares compared with those who received vehicle. The study was an exploratory analysis of data on the maintenance of response per Investigator’s Static Global Assessment (ISGA; ISGA score of 0 [clear] or 1 [almost clear]) during the CrisADe CONTROL study through week 52. Methods Exploratory endpoints were the time to ISGA response during the open-label run-in period, and the maintenance of ISGA response and the severity and duration of flares during the double-blind maintenance period. Outcomes were stratified by age (participants aged 3 months to
- Published
- 2024
- Full Text
- View/download PDF